DYN
Dyne Therapeutics, Inc.
$26.10
+0.46%
2026-08-21
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
-7.88
EPS (TTM)
$-3.26
ROE
-81.6%
Profit Margin
0.0%
Debt/Equity
33.23
Price/Book
6.06
Beta
1.08
Market Cap
$4.80B
Avg Volume (10D)
2.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$27.31
60D Low
$16.56
Avg Volume
2.2M
Latest Close
$26.10
Get breakout alerts for DYN
Sign up for Breakout Scanner to receive daily notifications when DYN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Dyne Therapeutics, Inc. (DYN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DYN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DYN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.